Abstract
Intracranial atherosclerotic disease is the second leading cause of stroke in the United States accounting for about 8–10% of all ischemic strokes. Its impact is even higher in Asian populations where intracranial atherosclerotic disease is responsible for approximately 50% of strokes. The treatment paradigms for this disease have evolved over the past few decades. Extracranial to intracranial bypass, which was one of the initial treatments of atherosclerotic disease, failed to provide any benefit in randomized trials. Maximal medical therapy is continuously improving with newer, more potent drugs, a better understanding of risk factors and their effect on atherosclerosis, and an improved ability to detect resistance to certain medication and provide alternatives. Endovascular therapy, despite initial promise, failed to show significant benefit in this population. However, more nuanced approaches to these patients are starting to emerge with a clear role for interventions, which include submaximal angioplasty, stenting, and indirect bypass. In this chapter, we discuss the epidemiology, natural history, risk factors, diagnosis, and treatment of intracranial atherosclerotic disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke Statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–596.
Bogousslavsky J, Van Melle G, Regli F. The Lausanne stroke registry: analysis of 1,000 consecutive patients with first stroke. Stroke. 1988;19(9):1083–92.
Sacco RL, Kargman DE, Gu Q, Zamanillo MC. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study Stroke. 1995;26(1):14–20.
Sangha RS, Naidech AM, Corado C, Ansari SA, Prabhakaran S. Challenges in the medical Management of Symptomatic Intracranial Stenosis in an urban setting. Stroke. 2017;48(8):2158–63.
Hass WK, Fields WS, North RR, Kircheff CNE II, Bauer RB. Joint study of extracranial arterial occlusion. II. Arteriography, techniques, sites, and complications. JAMA. 1968;203(11):961–8.
Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352(13):1305–16.
Qureshi AI, Safdar K, Patel M, Janssen RS, Frankel MR. Stroke in young black patients. Risk factors, subtypes, and prognosis. Stroke. 1995;26(11):1995–8.
Wityk RJ, Lehman D, Klag M, Coresh J, Ahn H, Litt B. Race and sex differences in the distribution of cerebral atherosclerosis. Stroke. 1996;27(11):1974–80.
White H, Boden-Albala B, Wang C, Elkind MS, Rundek T, Wright CB, et al. Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the northern Manhattan study. Circulation. 2005;111(10):1327–31.
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–e245.
Bae HJ, Lee J, Park JM, Kwon O, Koo JS, Kim BK, et al. Risk factors of intracranial cerebral atherosclerosis among asymptomatics. Cerebrovasc Dis. 2007;24(4):355–60.
Holmstedt CA, Turan TN, Chimowitz MI. Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment. Lancet Neurol. 2013;12(11):1106–14.
Chaturvedi S, Turan TN, Lynn MJ, Kasner SE, Romano J, Cotsonis G, et al. Risk factor status and vascular events in patients with symptomatic intracranial stenosis. Neurology. 2007;69(22):2063–8.
Turan TN, Makki AA, Tsappidi S, Cotsonis G, Lynn MJ, Cloft HJ, et al. Risk factors associated with severity and location of intracranial arterial stenosis. Stroke. 2010;41(8):1636–40.
Arenillas JF, Alvarez-Sabin J, Molina CA, Chacon P, Fernandez-Cadenas I, Ribo M, et al. Progression of symptomatic intracranial large artery atherosclerosis is associated with a proinflammatory state and impaired fibrinolysis. Stroke. 2008;39(5):1456–63.
Kim DE, Kim JY, Jeong SW, Cho YJ, Park JM, Lee JH, et al. Association between changes in lipid profiles and progression of symptomatic intracranial atherosclerotic stenosis: a prospective multicenter study. Stroke. 2012;43(7):1824–30.
Akins PT, Pilgram TK, Cross DT 3rd, Moran CJ. Natural history of stenosis from intracranial atherosclerosis by serial angiography. Stroke. 1998;29(2):433–8.
Feng X, Chan KL, Lan L, Abrigo J, Liu J, Fang H, et al. Stroke mechanisms in symptomatic intracranial atherosclerotic disease: classification and clinical implications. Stroke. 2019;50(10):2692–9.
Menon BK, Smith EE, Coutts SB, Welsh DG, Faber JE, Goyal M, et al. Leptomeningeal collaterals are associated with modifiable metabolic risk factors. Ann Neurol. 2013;74(2):241–8.
Lopez-Cancio E, Matheus MG, Romano JG, Liebeskind DS, Prabhakaran S, Turan TN, et al. Infarct patterns, collaterals and likely causative mechanisms of stroke in symptomatic intracranial atherosclerosis. Cerebrovasc Dis. 2014;37(6):417–22.
Kim JS, Nah HW, Park SM, Kim SK, Cho KH, Lee J, et al. Risk factors and stroke mechanisms in atherosclerotic stroke: intracranial compared with extracranial and anterior compared with posterior circulation disease. Stroke. 2012;43(12):3313–8.
Banerjee C, Chimowitz MI. Stroke caused by atherosclerosis of the major intracranial arteries. Circ Res. 2017;120(3):502–13.
Feldmann E, Wilterdink JL, Kosinski A, Lynn M, Chimowitz MI, Sarafin J, et al. The stroke outcomes and neuroimaging of intracranial atherosclerosis (SONIA) trial. Neurology. 2007;68(24):2099–106.
Liebeskind DS, Kosinski AS, Saver JL, Feldmann E, Investigators S. Computed tomography angiography in the stroke outcomes and neuroimaging of intracranial atherosclerosis (SONIA) study. Interv Neurol. 2014;2(4):153–9.
Mossa-Basha M, Alexander M, Gaddikeri S, Yuan C, Gandhi D. Vessel wall imaging for intracranial vascular disease evaluation. J Neurointerv Surg. 2016;8(11):1154–9.
Powers WJ, Clarke WR, Grubb RL Jr, Videen TO, Adams HP Jr, Derdeyn CP, et al. Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the carotid occlusion surgery study randomized trial. JAMA. 2011;306(18):1983–92.
Fiorella D, Levy EI, Turk AS, Albuquerque FC, Niemann DB, Aagaard-Kienitz B, et al. US multicenter experience with the wingspan stent system for the treatment of intracranial atheromatous disease: periprocedural results. Stroke. 2007;38(3):881–7.
Investigators SS. Stenting of symptomatic atherosclerotic lesions in the vertebral or intracranial arteries (SSYLVIA): study results. Stroke. 2004;35(6):1388–92.
Bose A, Hartmann M, Henkes H, Liu HM, Teng MM, Szikora I, et al. A novel, self-expanding, nitinol stent in medically refractory intracranial atherosclerotic stenoses: the wingspan study. Stroke. 2007;38(5):1531–7.
Costalat V, Maldonado IL, Zerlauth JB, Menjot N, Riquelme C, Machi P, et al. Endovascular treatment of symptomatic intracranial arterial stenosis: six-year experience in a single-center series of 42 consecutive patients with acute and mid-term results. Neurosurgery. 2010;67(6):1505–13; discussion 13-4.
Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turan TN, Janis LS, et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet. 2014;383(9914):333–41.
Zaidat OO, Fitzsimmons BF, Woodward BK, Wang Z, Killer-Oberpfalzer M, Wakhloo A, et al. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA. 2015;313(12):1240–8.
Millikan CH, Siekert RG, Shick RM. Studies in cerebrovascular disease. III. The use of anticoagulant drugs in the treatment of insufficiency or thrombosis within the basilar arterial system. Proc Staff Meet Mayo Clin. 1955;30(6):116–26.
Prognosis of patients with symptomatic vertebral or basilar artery stenosis. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group. Stroke. 1998;29(7):1389–92.
Chimowitz MI, Kokkinos J, Strong J, Brown MB, Levine SR, Silliman S, et al. The warfarin-aspirin symptomatic intracranial disease study. Neurology. 1995;45(8):1488–93.
Thijs VN, Albers GW. Symptomatic intracranial atherosclerosis: outcome of patients who fail antithrombotic therapy. Neurology. 2000;55(4):490–7.
Kasner SE, Lynn MJ, Chimowitz MI, Frankel MR, Howlett-Smith H, Hertzberg VS, et al. Warfarin vs aspirin for symptomatic intracranial stenosis: subgroup analyses from WASID. Neurology. 2006;67(7):1275–8.
Turan TN, Maidan L, Cotsonis G, Lynn MJ, Romano JG, Levine SR, et al. Failure of antithrombotic therapy and risk of stroke in patients with symptomatic intracranial stenosis. Stroke. 2009;40(2):505–9.
Wong KS, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010;9(5):489–97.
Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis (CARESS) trial. Circulation. 2005;111(17):2233–40.
Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369(1):11–9.
Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke. 2005;36(4):782–6.
Kwon SU, Hong KS, Kang DW, Park JM, Lee JH, Cho YJ, et al. Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis. Stroke. 2011;42(10):2883–90.
Turan TN, Cotsonis G, Lynn MJ, Chaturvedi S, Chimowitz M. Warfarin-aspirin symptomatic intracranial disease trial I. relationship between blood pressure and stroke recurrence in patients with intracranial arterial stenosis. Circulation. 2007;115(23):2969–75.
Turan TN, Nizam A, Lynn MJ, Egan BM, Le NA, Lopes-Virella MF, et al. Relationship between risk factor control and vascular events in the SAMMPRIS trial. Neurology. 2017;88(4):379–85.
Powers WJ, Clarke WR, Grubb RL Jr, Videen TO, Adams HP Jr, Derdeyn CP, et al. Lower stroke risk with lower blood pressure in hemodynamic cerebral ischemia. Neurology. 2014;82(12):1027–32.
Amin-Hanjani S, Turan TN, Du X, Pandey DK, Rose-Finnell L, Richardson D, et al. Higher stroke risk with lower blood pressure in hemodynamic Vertebrobasilar disease: analysis from the VERiTAS study. J Stroke Cerebrovasc Dis. 2017;26(2):403–10.
Group EIBS. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. N Engl J Med. 1985;313(19):1191–200.
Gonzalez NR, Jiang H, Lyden P, Song S, Schlick K, Dumitrascu O, et al. Encephaloduroarteriosynangiosis (EDAS) revascularization for symptomatic intracranial atherosclerotic steno-occlusive (ERSIAS) phase-II objective performance criterion trial. Int J Stroke. 2020;1747493020967256.
Alexander MJ, Zauner A, Chaloupka JC, Baxter B, Callison RC, Gupta R, et al. WEAVE trial: final results in 152 on-label patients. Stroke. 2019;50(4):889–94.
Alexander MJ, Zauner A, Gupta R, Alshekhlee A, Fraser JF, Toth G, et al. The WOVEN trial: wingspan one-year vascular events and neurologic outcomes. J Neurointerv Surg. 2020.
Stapleton CJ, Chen YF, Shallwani H, Vakharia K, Turan TN, Woo HH, et al. Submaximal angioplasty for symptomatic intracranial atherosclerotic disease: a meta-analysis of Peri-procedural and long-term risk. Neurosurgery. 2020;86(6):755–62.
Silvestrini M, Paolino I, Vernieri F, Pedone C, Baruffaldi R, Gobbi B, et al. Cerebral hemodynamics and cognitive performance in patients with asymptomatic carotid stenosis. Neurology. 2009;72(12):1062–8.
Marshall RS, Festa JR, Cheung YK, Chen R, Pavol MA, Derdeyn CP, et al. Cerebral hemodynamics and cognitive impairment: baseline data from the RECON trial. Neurology. 2012;78(4):250–5.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Rahme, R.J., Veznedaroglu, E. (2022). Intracranial Atherosclerotic Disease. In: Mascitelli, J.R., Binning, M.J. (eds) Introduction to Vascular Neurosurgery. Springer, Cham. https://doi.org/10.1007/978-3-030-88196-2_14
Download citation
DOI: https://doi.org/10.1007/978-3-030-88196-2_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-88195-5
Online ISBN: 978-3-030-88196-2
eBook Packages: MedicineMedicine (R0)